CAMBRIDGE, MA, Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced the closing of a $14 million financing round.
Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced the closing of a $14 million financing round backed by two new investors, Eli Lilly and Company and the strategic investment arm of the Singapore Economic Development Board, EDBI, as well as continued support from existing investors ClavystBio, Polaris Partners and S32.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
